These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 33135506)

  • 1. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
    Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
    Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
    [No Abstract]   [Full Text] [Related]  

  • 2. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [No Abstract]   [Full Text] [Related]  

  • 10. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Zhang X; Zhang G; Wang J; Bi J
    Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darolutamide for treatment of castration-resistant prostate cancer.
    Rhea LP; Mendez-Marti S; Aragon-Ching JB
    Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darolutamide (Nubeqa) for prostate cancer.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):201-202. PubMed ID: 31999669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.